Peptides for longevity and cell health, ranked by human evidence

Peptides studied for ageing, mitochondria, senescent cells and cellular stress. The evidence here is early: read the counts and grades closely. They are ranked by an evidence score that weighs the grade of the evidence, the human trials counted in PubMed, and regulatory status — shown in the columns so any rank can be checked. A high score means a peptide is well studied and often approved for something, not that it is right, safe or legal for this goal. Nothing here is medical advice, and Grey Peptides sells nothing and links to no vendor. See all goals or the plainer browse by goal map.

Evidence grade

Regulatory status

Search name

Has a human trial on this page

36 peptides · sorted by evidence score (click a column to re-sort)

Peptide	Grade	Human studies	RCTs	Max trial phase	Regulatory	Dose	Score
Elamipretide	High	202	19	Phase 4	FDA approved	subcutaneous →	100
SS-31 (Elamipretide)	High	108	16	Phase 2	FDA approved	subcutaneous →	100
GDF15	High	4,421	183	Phase 4	In trials	—	80
Melatonin	Medium	16,290	1,205	Phase 4	Supplement	—	65
Klotho Peptide	Medium	2,669	67	Phase 4	Research only	—	55
Carnosine	Medium	1,386	158	Phase 4	Supplement	—	55
NAD+	Medium	314	16	Phase 4	Research only	—	55
Prostatilen	Low	18	2	—	Approved abroad	intramuscular →	50
Retinalamin	Low	16	3	—	Approved abroad	intramuscular →	50
SHLP2	Medium	16	0	—	Research only	—	45
Thymalin	Low	200	2	—	Approved abroad	—	40
Thymogen	Low	94	7	—	Approved abroad	—	40
Glutathione	Low	61,221	1,879	Phase 4	Research only	—	35
Humanin	Low	335	6	—	Research only	—	35
GDF11	Low	322	4	—	Research only	—	35
Vilon	Low	229	3	—	Research only	—	35
MOTS-c	Low	152	4	Phase 2	Research only	—	35
Epithalamin	Low	30	5	—	Research only	—	35
Vesugen	Low	27	0	—	Research only	—	35
Pinealon	Low	23	0	—	Research only	oral (capsule) →	35
Ovagen	Low	15	2	—	Research only	—	35
Prostamax	Low	8	0	—	Approved abroad	—	30
Testagen	Low	1	0	Phase 2	Approved abroad	—	30
Chonluten	Low	58	0	—	Research only	—	25
Epithalon	Low	51	0	Early Phase 1	Research only	—	25
Cartalax	Low	35	0	—	Research only	—	25
Cardiogen	Low	26	0	—	Research only	—	25
Cortagen	Low	26	0	—	Research only	—	25
Livagen	Low	19	0	—	Research only	—	25
SHLP6	Low	15	0	—	Research only	—	25
FOXO4-DRI	Low	9	0	—	Preclinical	—	25
Bronchogen	Low	7	0	—	Research only	—	25
Cerluten	Low	0	0	—	Approved abroad	—	25
Endoluten	Low	0	0	—	Approved abroad	—	25
Ventfort	Low	0	0	—	Approved abroad	—	25
Visoluten	Low	0	0	—	Approved abroad	—	25

Other goals: Weight loss and metabolism · Healing, injury and recovery · Skin and hair · Focus, mood and the brain · Growth hormone and body composition · Heart and circulation · Sexual and reproductive health · Immune defence and infection · Diagnostic and research tools · In development

How the evidence score works

Evidence score (0-100), a transparent ranking aid, not a verdict. grade: high=60, medium=40, low=20, ungraded=0. Human trial: an on-site read-and-cited randomized or clinical trial = +15, else any PubMed human-indexed record = +5, else 0. RCT literature: PubMed lists >=1 randomized controlled trial = +10. Regulatory: FDA-approved = +15, in trials / approved-abroad / in development = +5, else 0. Every component is stored on each record so the number can be re-derived; volume and grade are shown together so neither misleads.

“Human studies” and “RCTs” are PubMed record counts for the peptide (read 2026-11-07 from the counts behind the Evidence Explorer); a count is how much research exists and of what kind, never proof a peptide works. “Grade” is our editorial reading of the evidence — see how we grade evidence. The “Dose” column links to the entry for each peptide that carries a dose from a regulator’s label or a published human study — where the amount is shown with its source; the amount is never reprinted here without that source, and many research peptides have no human dose, shown as —. Of 660 peptides, 607 have at least one human-indexed PubMed record, 324 cite a human trial on their page, 124 are FDA-approved, and 271 carry a sourced dose.